These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

544 related items for PubMed ID: 16052584

  • 21. Identification of cutpoints for acceptable health status and important improvement in patient-reported outcomes, in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Kvamme MK, Kristiansen IS, Lie E, Kvien TK.
    J Rheumatol; 2010 Jan; 37(1):26-31. PubMed ID: 19955045
    [Abstract] [Full Text] [Related]

  • 22. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis.
    Kastbom A, Bratt J, Ernestam S, Lampa J, Padyukov L, Söderkvist P, Skogh T.
    Arthritis Rheum; 2007 Feb; 56(2):448-52. PubMed ID: 17265480
    [Abstract] [Full Text] [Related]

  • 23. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis.
    Barkham N, Kong KO, Tennant A, Fraser A, Hensor E, Keenan AM, Emery P.
    Rheumatology (Oxford); 2005 Oct; 44(10):1277-81. PubMed ID: 16105913
    [Abstract] [Full Text] [Related]

  • 24. [The impact of therapy with TNF-blockers on health-related quality of life in rheumatoid arthritis patients. A pilot study].
    Abalos Medina GM, Ruiz Villaverde G, Sánchez Cano D, Ruiz Villaverde R, Ramírez Rodrigo J, Raya Álvarez E, Villaverde Gutiérrez C.
    Reumatol Clin; 2011 Oct; 7(3):167-71. PubMed ID: 21794808
    [Abstract] [Full Text] [Related]

  • 25. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial.
    Park JH, Seo GY, Lee JS, Kim TH, Yoo DH.
    J Rheumatol; 2009 Oct; 36(10):2158-63. PubMed ID: 19723901
    [Abstract] [Full Text] [Related]

  • 26. Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis.
    Gengenbacher M, Sebald HJ, Villiger PM, Hofstetter W, Seitz M.
    Ann Rheum Dis; 2008 May; 67(5):620-4. PubMed ID: 17720725
    [Abstract] [Full Text] [Related]

  • 27. Characteristics and treatment responses of patients satisfying the BSR guidelines for anti-TNF in ankylosing spondylitis.
    Gadsby K, Deighton C.
    Rheumatology (Oxford); 2007 Mar; 46(3):439-41. PubMed ID: 17255137
    [Abstract] [Full Text] [Related]

  • 28. The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study.
    Heiberg MS, Kaufmann C, Rødevand E, Mikkelsen K, Koldingsnes W, Mowinckel P, Kvien TK.
    Ann Rheum Dis; 2007 Aug; 66(8):1038-42. PubMed ID: 17213251
    [Abstract] [Full Text] [Related]

  • 29. Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability.
    Baumgartner SW, Fleischmann RM, Moreland LW, Schiff MH, Markenson J, Whitmore JB.
    J Rheumatol; 2004 Aug; 31(8):1532-7. PubMed ID: 15290731
    [Abstract] [Full Text] [Related]

  • 30. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
    Catrina AI, af Klint E, Ernestam S, Catrina SB, Makrygiannakis D, Botusan IR, Klareskog L, Ulfgren AK.
    Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
    [Abstract] [Full Text] [Related]

  • 31. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
    De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F.
    Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
    [Abstract] [Full Text] [Related]

  • 32. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.
    Brandt J, Listing J, Haibel H, Sörensen H, Schwebig A, Rudwaleit M, Sieper J, Braun J.
    Rheumatology (Oxford); 2005 Mar; 44(3):342-8. PubMed ID: 15561737
    [Abstract] [Full Text] [Related]

  • 33. Fatigue, rheumatoid arthritis, and anti-tumor necrosis factor therapy: an investigation in 24,831 patients.
    Wolfe F, Michaud K.
    J Rheumatol; 2004 Nov; 31(11):2115-20. PubMed ID: 15517621
    [Abstract] [Full Text] [Related]

  • 34. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.
    Seong SS, Choi CB, Woo JH, Bae KW, Joung CL, Uhm WS, Kim TH, Jun JB, Yoo DH, Lee JT, Bae SC.
    J Rheumatol; 2007 Apr; 34(4):706-11. PubMed ID: 17309133
    [Abstract] [Full Text] [Related]

  • 35. Etanercept in adult patients with early onset ankylosing spondylitis.
    Inman RD, Clegg DO, Davis JC, Whitmore JB, Solinger A.
    J Rheumatol; 2006 Aug; 33(8):1634-6. PubMed ID: 16881118
    [Abstract] [Full Text] [Related]

  • 36. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, REFLEX Trial Group.
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [Abstract] [Full Text] [Related]

  • 37. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.
    Elkayam O, Bashkin A, Mandelboim M, Litinsky I, Comaheshter D, Levartovsky D, Mendelson E, Wigler I, Caspi D, Paran D.
    Semin Arthritis Rheum; 2010 Jun; 39(6):442-7. PubMed ID: 19246078
    [Abstract] [Full Text] [Related]

  • 38. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis.
    Kiortsis DN, Mavridis AK, Filippatos TD, Vasakos S, Nikas SN, Drosos AA.
    J Rheumatol; 2006 May; 33(5):921-3. PubMed ID: 16541480
    [Abstract] [Full Text] [Related]

  • 39. Responsiveness and discriminative capacity of the assessments in ankylosing spondylitis disease-controlling antirheumatic therapy core set and other outcome measures in a trial of etanercept in ankylosing spondylitis.
    Wanders AJ, Gorman JD, Davis JC, Landewe RB, van der Heijde DM.
    Arthritis Rheum; 2004 Feb 15; 51(1):1-8. PubMed ID: 14872448
    [Abstract] [Full Text] [Related]

  • 40. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept.
    Braun J, Baraliakos X, Listing J, Sieper J.
    Arthritis Rheum; 2005 Aug 15; 52(8):2447-51. PubMed ID: 16052578
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.